Moderna’s Covid jab shows 94.5% efficacy in clinical trials

Moderna’s Covid jab shows 94.5% efficacy in clinical trials

Second set of positive results in eight days further boosts hope vaccines will be effective

US biotech Moderna said its Covid-19 vaccine had shown 94.5 per cent efficacy in clinical trials, in the second positive set of results for a potential coronavirus shot in the past eight days.

Last week, US giant Pfizer and Germany’s BioNTech also said their vaccine, which uses the same messenger RNA technology, was found to be more than 90 per cent effective.

The Moderna finding, hot on the heels of that breakthrough, will further boost optimism that the world can turn the corner in the management of the pandemic.

Stéphane Bancel, Moderna’s chief executive, said the moment was “pivotal”.

“This positive interim analysis from our phase-3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease,” he said.

Out of 30,000 participants in the clinical trials, 95 had been identified with confirmed cases of Covid-19, the company said. Among those infected, only five people had received the two-dose vaccine, known as mRNA-1273, while 90 had received a placebo.